The studies were conducted in collaboration with Stem Pharm, Inc., utilizing their proprietary platform of human neuro-immune organoids. These organoids closely mimic human brain tissue, incorporating a complex cellular environment relevant to neurodegenerative diseases. The results indicate that INM-901 significantly reduces neuroinflammation in both general and Alzheimer's-specific models, showcasing a dose-dependent reduction in key pro-inflammatory markers such as IL-6 and IL-8.
Dr. Eric Hsu, InMed's Senior Vice President of Preclinical Research and Development, emphasized the importance of these findings, stating that they represent a critical milestone for the INM-901 program. The consistency of the anti-inflammatory effects across various models enhances confidence in the compound's potential to provide clinical benefits for patients suffering from neuroinflammatory conditions.
Looking ahead, InMed plans to conduct a pre-IND meeting with the U.S. Food and Drug Administration in the third quarter of 2026, followed by IND-enabling pharmacology and toxicology studies. The company aims to submit an IND and initiate a Phase 1 clinical trial for INM-901 in 2027, contingent upon regulatory feedback and the completion of necessary studies. This proactive approach positions InMed favorably within the competitive landscape of Alzheimer's treatment development, where targeting neuroinflammation is gaining traction as a strategic therapeutic target.
